Webcast Alert: Isis Pharmaceuticals' Third Quarter 2011 Financial Results Conference Call

CARLSBAD, Calif., Oct. 25, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:

What:

Isis Pharmaceuticals' Third Quarter 2011 Financial Results Conference Call



When:

Monday, November 07, 2011 at 4:30 p.m. ET / 1:30 p.m. PT



Where:

www.isispharm.com



How:

Live on the Internet.  Simply log onto our Web site listed above.



Contacts:

Kristina Lemonidis


Director, Investor Relations


(760) 603-2490




Amy Blackley, Ph.D.


Assistant Director, Corporate Communications


(760) 603-2772



If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 24 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic and severe and rare/neurodegenerative diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, mipomersen, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

SOURCE Isis Pharmaceuticals, Inc.

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.